Paeonol Suppresses Proliferation and Motility of Non-Small-Cell Lung Cancer Cells by Disrupting STAT3/NF-κB Signaling

Lei Zhang1,2, Wen-Xu Chen1,3, Ling-Li Li2

  • 1Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Hospital, Hefei, China.

Frontiers in Pharmacology
|January 14, 2021
PubMed

Insights

Paeonol effectively inhibits non-small cell lung cancer (NSCLC) growth and metastasis by targeting inflammatory pathways. This study highlights paeonol as a potential anti-cancer agent for NSCLC treatment.

Area of Science:

  • Pharmacology and Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Targeting the tumor microenvironment is a key anti-cancer strategy.
  • Paeonol, a phenolic compound, possesses anti-inflammatory and anti-tumor properties.
  • The anti-cancer effects of paeonol on non-small cell lung carcinoma (NSCLC) require further investigation.

Purpose of the Study:

  • To evaluate the anti-proliferative and anti-metastatic effects of paeonol on NSCLC.
  • To elucidate the underlying molecular mechanisms of paeonol's action in NSCLC.

Main Methods:

  • In vitro assays assessed NSCLC cell proliferation, migration, and invasion.
  • ELISA and Western blot analyzed inflammatory cytokines and epithelial-mesenchymal transition (EMT) markers.
  • In vivo studies utilized a nude mouse xenograft model to evaluate anti-tumor efficacy and apoptosis.

Main Results:

  • Paeonol significantly inhibited NSCLC cell migration and invasion in vitro.
  • Paeonol reduced secretion of key inflammatory cytokines (TNF-α, IL-6, IL-1β, TGF-β).
  • Paeonol suppressed tumor growth in vivo and disrupted STAT3 and NF-κB signaling pathways.

Conclusions:

  • Paeonol demonstrates potent anti-proliferative and anti-metastatic activity against NSCLC.
  • The anti-cancer effects are linked to the inhibition of STAT3 and NF-κB signaling.
  • Paeonol represents a promising candidate for NSCLC chemotherapy and metastasis prevention.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.8K